A Randomized, Dose-escalation Phase I/IIa Trial With Controlled Human Malaria Infection to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of an Investigational RNA-based Vaccine for Prevention of P. Falciparum Malaria in Healthy Malaria naïve Adults
Latest Information Update: 13 Jun 2025
At a glance
- Drugs BNT 165 (Primary)
- Indications Malaria
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioNTech
Most Recent Events
- 09 Apr 2025 Planned primary completion date changed from 1 Sep 2025 to 1 May 2025.
- 06 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2024 Planned number of patients changed from 138 to 177.